Diabetes Gestacional - Rastreio Pós-Parto

Introdução: Um terço das mulheres com diabetes gestacional terá o diagnóstico de diabetes ou alteração do metabolismo da glicose no rastreio pós-parto. Objectivo: Avaliar a percentagem de mulheres submetidas a rastreio pós-parto e associar o resultado com a história materna. Métodos: Estudo retrospectivo de 1013 gravidezes com diabetes gestacional (2005-2009). Dividiu-se a população em dois grupos de acordo com o resultado: normal (grupo 1) e com diabetes ou alteração do metabolismo da glicose (grupo 2). Para ambos os grupos foram avaliados: idade materna, índice de massa corporal, ganho de peso na gravidez, idade gestacional do diagnóstico, necessidade de administração de insulina, factores de risco para diabetes gestacional e peso do recém-nascido. Resultados: O rastreio pós-parto foi realizado em 76,8% das mulheres (n=778). O teste foi considerado normal (grupo 1) em 628 mulheres(80,7%) e alterado (grupo 2) em 150 mulheres (19,3%). O Grupo 2 teve mulheres mais velhas (idade média de 34 vs 33 anos;p-value 0,013), com maior índice de massa corporal (28,5 vs 25,8kg / cm2; p-value 0,000), maior número de mulheres com história familiar em primeiro grau de diabetes mellitus (50,3% vs 39,9%; p-value 0,026) e história pessoal de macrossomia prévia (12,1% vs 5,4%; p-value 0,003). O diagnóstico mais precoce da diabetes gestacional foi também feito nesse grupo (27 vs 31 semanas; p-value 0,000) e uma maior percentagem efectuou insulina (41% vs 15%; p-value 0,000), tendo iniciado mais cedo a sua administração (28 vs 30 semanas; p-value 0,010). Verificou-se uma maior percentagem de grávidas multíparas no grupo 2 (64% vs 49,4%; p-value = 0,001) e um maior número de casos de recém-nascidos grandes para a idade gestacional (17,1% vs 8,3%; p-value = 0,001). A história pessoal de diabetes gestacional e ganho de peso durante a gestação foi semelhante nos dois grupos. Conclusões: As mulheres com alteração nos resultados do rastreio pós-parto são geralmente mais velhas, mais pesadas, multíparas, com história familiar em primeiro grau de diabetes Mellitus e história pessoal de macrossomia prévia. O diagnóstico de diabetes gestacional foi mais precoce neste grupo, mais frequentemente necessitaram de terapêutica com insulina com início mais cedo e verificou-se um maior número de recém-nascidos grandes para a idade gestacional.

Oral Contraceptive Use and Clinical Outcomes in Patients with Multiple Sclerosis

Experimental and clinical data suggest a role of sex steroids in the pathogenesis of multiple sclerosis (MS). Scant information is available about the potential effect of oral contraceptive (OC) use on the prognosis of the disease. We aimed to evaluate this. The study population consisted of 132 women with relapsing-remitting MS before receiving disease modifying treatment and a mean disease duration 6.2 (SD 5.1) years. Three groups of patients were distinguished according to their OC behavior: [1] never-users, patients who never used OC [2] past-users, patients who stopped OC use before disease onset, and [3] after-users, those who used these drugs after disease onset. Multiple linear and logistic regression models were used to analyze the association between oral contraceptive use and annualized relapse rates, disability accumulation and severity of the disease. After-user patients had lower Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) values than never users (p<0.001 and p=0.002, respectively) and past users (p=0.010 and p=0.002, respectively). These patients were also more likely to have a benign disease course (MSSS<2.5) than never and past users together (OR: 4.52, 95%CI: 2.13-9.56, p<0.001). This effect remained significant after adjustment for confounders, including smoking and childbirths (OR: 2.97, 95%CI: 1.24, 6.54, p=0.011 and for MSSS β: -1.04; 95% C.I. -1.78, -0.30, p=0.006). These results suggest that OC use in women with relapsing-remitting MS is possible associated with a milder disabling disease course.

Variant Rett Syndrome in a Girl with a Pericentric X-Chromosome Inversion Leading to Epigenetic Changes and Overexpression of the MECP2 Gene

Rett syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene. We investigated the genetic basis of disease in a female patient with a Rett-like clinical. Karyotype analysis revealed a pericentric inversion in the X chromosome -46,X,inv(X)(p22.1q28), with breakpoints in the cytobands where the MECP2 and CDKL5 genes are located. FISH analysis revealed that the MECP2 gene is not dislocated by the inversion. However, and in spite of a balanced pattern of X inactivation, this patient displayed hypomethylation and an overexpression of the MECP2 gene at the mRNA level in the lymphocytes (mean fold change: 2.55±0.38) in comparison to a group of control individuals; the expression of the CDKL5 gene was similar to that of controls (mean fold change: 0.98±0.10). No gains or losses were detected in the breakpoint regions encompassing known or suspected transcription regulatory elements. We propose that the de-regulation of MECP2 expression in this patient may be due to alterations in long-range genomic interactions caused by the inversion and hypothesize that this type of epigenetic de-regulation of the MECP2 may be present in other RTT-like patients.

Clinical and Genetic Characterization of Portuguese Patients with Pseudohypoparathyroidism Type Ib

Patients with pseudohypoparathyroidism type Ib (PHP-Ib) present hypocalcemia and hyperphosphatemia, as a consequence of a resistance to PTH action, through its G-protein-coupled receptor, in the renal tubules. This resistance results from tissue-specific silencing of the G-protein alpha-subunit (G(s)α), due to imprinting disruption of its encoding locus--GNAS. In familial PHP-Ib, maternally inherited deletions at the STX16 gene are associated to a regional GNAS methylation defect. In sporadic PHP-Ib, broad methylation changes at GNAS arise from unknown genetic causes. In this study, we describe the clinical presentation of PHP-Ib in four Portuguese patients (two of whom were siblings), and provide further insight for the management of patients with this disease. The diagnosis of PHP-Ib was made after detection of GNAS imprinting defects in each of the cases. In the siblings, a regional GNAS methylation change resulted from a known 3.0 kb STX16 deletion. In the other two patients, the broad methylation defects at GNAS, which were absent in their relatives, resulted from genetic alterations that remain to be identified. We report the first clinical and genetic study of Portuguese patients with PHP-Ib. The genetic identification of a hereditary form of this rare disease allowed an early diagnosis, and may prevent hypocalcemia-related complications.